Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
Researchers from McGill University found that nurses who receive 40 minutes of bright light exposure prior to their night shifts experience less fatigue and commit fewer mistakes. Following their shifts, the nurses also slept better.
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
Oncology Drug Shortages Persist, but Continue to Evolve
2.
DBT Reduced Suicide Attempts in Adolescents with Bipolar Disorder.
3.
Telehealth in the pandemic era resulted in fewer therapy interruptions.
4.
Accurately identified high-grade prostate cancer through urine testing.
5.
Q&A: Odds of surviving cancer drop drastically when credit score dips
1.
The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025
2.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
3.
Unlocking the Immune Arsenal: A Revolution in Cancer Treatment
4.
Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide
5.
Surgery for Tracheoesophageal Fistula: What to Expect Before, During, and After
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge